Christopher Bredeson, MD, MSc, FRCPC
Director, Hematologic Malignancies
Professor of Medicine
Dr. Bredeson is Professor of Medicine at the Medical College of Wisconsin, Division of Neoplastic Diseases and Related Disorders. He specializes in Hematologic Malignancies particularly leukemia & bone marrow failure states and hematopoietic cell transplantation. He graduated from the University of Ottawa in 1987 and also received from there his Master of Science in Epidemiology in 1997. He completed an Internal Medicine residency at the University of Ottawa and a Hematology residency at the University of British Columbia. He then went on to complete a Leukemia and Bone Marrow Transplantation fellowship at the University of British Columbia, Vancouver. Dr. Bredeson is board certified in Hematology and Internal Medicine.
Dr Bredeson is an active member of the American Society of Hematology, the American Society of Blood and Marrow Transplantation, the Blood and Marrow Transplant Clinical Trials Network and the National Institutes of Health, teaching clinical research methods, serving on committees, and participating in review panels for these organizations.
His research interests center around observational studies and prospective clinical trials in leukemia, myelodysplastic syndromes and hematopoietic cell transplantation.
Selected Publications
BREDESON, CN, Leger, C, Couban, S, Simpson, D, Huebsch, L, Walker, I, Shore, T, , Howson-Jan, K, Panzarella, T, Messner, H, Barnett, M, Lipton, J. An evaluation of the donor experience in the Canadian multicenter randomized trial of bone marrow versus peripheral blood allografting. Biol Blood Marrow Transplant 10:405-414, 2004.
BREDESON CN, Pavletic SZ. Considerations when designing a clinical trial of haematopoietic stem cell transplantation for autoimmune disease. Best Pract Res Clin Haematol 17:327-343, 2004.
Griffith LM, Pavletic SZ, Tyndall A, BREDESON, CN, et al. Feasibility of allogeneic Hematopoietic stem cell transplantation for autoimmune disease: position statement fro ma National Institute of Allergy and Infectious Diseases and national Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biol Blood Marrow Transplant 11:862-870, 2005.
Passweg JR, Perez W, Eapen M, Camitta BM, Gluckman E, Hinerberger w, Hows JM, Marsh JC, Pasquini R, Schrezenmeier H, Socie G, Zhang MJ, BREDESON, CN. Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. Bone Marrow Transplant 37:641-649, 2006.
BREDESON CN, Zhang MJ, Agovi MA, Bacigalupo A, Bahlis NJ, Ballen K, Brown C, Chaudhry MA, Horowitz MM, Kurian S, Quinlan D, Muehlenbien CE, Russell JA, Savoie L, Rizzo JD, Stewart DA. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biol Blood Marrow Transplant. 2008 Sep;14(9):993-1003. PMID: 18721762 [PubMed - in process]
Marks DI, Pérez WS, He W, Zhang MJ, Bishop MR, Bolwell BJ, BREDESON CN, Copelan EA, Gale RP, Gupta V, Hale GA, Isola LM, Jakubowski AA, Keating A, Klumpp TR, Lazarus HM, Liesveld JL, Maziarz RT, McCarthy PL, Sabloff M, Schiller G, Sierra J, Tallman MS, Waller EK, Wiernik PH, Weisdorf DJ. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood. 2008 Jul 15;112(2):426-34. Epub 2008 Apr 8. PMID: 18398065 [PubMed - indexed for MEDLINE]
Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, BREDESON CN, Burns LJ, Cairo MS, Freytes CO, Goldstein SC, Hale GA, Inwards DJ, Lemaistre CF, Maharaj D, Marks DI, Schouten HC, Slavin S, Vose JM, Lazarus HM, van Besien K. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant. 2008 Feb;14(2):236-45. PMID: 18215784 [PubMed - indexed for MEDLINE]
Ferrara JL, Anasetti C, Stadtmauer E, Antin J, Wingard J, Lee S, Levine J, Schultz K, Appelbaum F, Negrin R, Giralt S, BREDESON C, Heslop H, Horowitz M. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007. Biol Blood Marrow Transplant. 2007 Nov;13(11):1268-85. PMID: 17950914 [PubMed - indexed for MEDLINE]
Leger C, Sabloff M, McDiarmid S, Bence-Bruckler I, Atkins H, BREDESON C, Zhang H, Huebsch L. Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma. Ann Hematol. 2006 Oct;85(10):723-9. Epub 2006 Jul 11. PMID: 16832675 [PubMed - indexed for MEDLINE]
Devetten MP, Hari PN, Carreras J, Logan BR, Besien, KV, BREDESON CN, Freytes CO, Gale RP, Gibson J, Giralt SA, Goldstein SC, Gupta V, Marks DI, Maziarz RT, Vose JM, Lazarus HM, Anderlini P. Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation. 2009:15(1):109-17. DOI: 10.1016/J.bbmt.2008.11.011
Ringden O, Pavletic SZ, Anasetti C, Barrett AJ, Wang T, Wang D, Antin JH, Di Bartolomeo P, Bolwell BJ, BREDESON C, Cairo MS, Gale RP, Gupta V, Hahn T, Hale GA, Halter J, Jagasia M, Litzow MR, Locatelli F, Marks DI, McCarthy PL, Cowan MJ, Petersdorf EW, Russell JA, Schiller GJ, Schouten H, Spellman S, Verdonck LF, Wingard JR, Horowitz MM, Arora M. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood. 2008 Dec:4 [Epub ahead of print]
Devetten MP, Hari PN, Carreras J, Logan BR, Van Besien K, BREDESON CN, Freytes CO, Gale RP, Gibson J, Giralt SA, Goldstein SC, Gupta V, Marks DI, Maziarz RT, Vose JM, Lazarus HM, Anderlini P. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2009 Jan;15 (1) :109-17.
Logan B, Leifer E, BREDESON C, Horowitz M, Ewell M, Carter S, Geller N. Use of biological assignment in hematopoietic stem cell transplantation clinical trials. Clin Trials. 2008;5(6) :607-16.